Login to Your Account



Other News To Note


Wednesday, March 30, 2011
Heptares Therapeutics Ltd.of Welwyn Garden City, UK, said it has demonstrated that fragment-based drug discovery methods can be applied to the screening of G protein-coupled receptors (GPCRs) by stabilizing the GPCRs with StaR technology. Results were published in a recent issue of Methods in Enzymology.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription